Retractable Technologies, Inc.
RVPRetractable Technologies, Inc. in brief
Retractable Technologies, Inc. is a listed company in the Medical Instruments industry, based in Little Elm, Texas, USA. Its market value was $18 M on 28 October 2026, which makes it the 24,683rd largest listed company in the world and the 4,177th largest in the USA on this site. In the year to December 2025 it had sales of $38 M and a net loss of $13 M. It employs about 201 people and Thomas J. Shaw is its chief executive. Its largest product and service lines by sales in 2025 were Syringes (65%), EasyPoint Needles (31%) and Blood Collection Products (4%). Its shares trade under the symbol RVP (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Retractable Technologies, Inc.
Retractable Technologies, Inc. was incorporated in Texas in 1994. Our business is the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. We have manufacturing facilities in Little Elm, Texas and use manufacturers in China as well. Our syringes are well-suited for administering vaccinations.
On September 13, 2024, the Office of the U.S. Trade Representative revealed final adjustments to increase tariffs on certain goods imported from China under Section 301 of the Trade Act of 1974. Among those products included were syringes and needles, at a rate of 100%. Beginning in early 2025 and throughout much of the year, additional widespread tariffs were imposed on most products imported into the U.S. citing authority under the International Emergency Economic Powers Act. Those tariffs were in addition to the Section 301 tariffs which existed at the time. Throughout 2025, the prevailing tariff rates on various products and certain countries of origin, including many of our products, fluctuated greatly. These fluctuations negatively impacted our ability to predict the cost of importing certain goods or groups of goods and negatively impacted our business. In February 2026, the U.S. Supreme Court ruled that the President’s use of IEEPA to impose reciprocal tariffs exceeded his authority and that the IEEPA tariffs must be vacated. Looking forward after the Supreme Court’s ruling, the 2024 Section 301 tariff of 100% on syringes and needles from China remains unchanged. Additionally, following the Supreme Court’s ruling on the tariffs imposed under IEEPA, effective February 20, 2026 a 10% ad valorem duty went into effect under Section 122 of the Trade Act, which is in addition to the above-mentioned Section 301 tariffs.
From the company's annual report filed with the US SEC: read the report
Retractable Technologies, Inc. timeline
- 2000
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2001
- 🔔· approximateInitial public offering on NYSE
- 2021
- 💰Record revenue of $188 millionFY2021, the highest of the 8 years on record.
- 💰Record net income of $56 millionFY2021, the highest profit of the 4 years on record.
Events of Retractable Technologies, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,137 (Jan 2020) · #2,796 (Jan 2021) · #3,763 (Jan 2022) · #4,692 (Dec 2022) · #4,958 (Jul 2023) · #4,222 (Jan 2024) · #2,304 (Mar 2026) · #3,938 (Aug 2026) · #4,180 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.5×
- Price / book
- 0.2×
- Free cash flow yield
- -73.6%
- Net margin (TTM)
- -10.0%
- Operating margin
- -55.3%
- Return on equity
- -4.5%
- Liabilities / assets
- 47.9%
- Net debt
- $-2M
- Revenue growth
- +15.8%
- R&D / revenue
- 1.8%
- Revenue per employee
- $190 K
- Profit per employee
- $-63 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $38M | +15.8% | $-21M | $-13M | -32.8% |
| Dec 2024 | $33M | -24.2% | $-21M | $-12M | -36.0% |
| Dec 2023 | $44M | -54.0% | $-11M | $-7M | -16.1% |
| Dec 2022 | $95M | -49.7% | $-1M | $5M | 5.4% |
| Dec 2021 | $188M | +130.1% | $73M | $56M | 29.8% |
| Dec 2020 | $82M | +95.8% | $24M | $24M | 29.6% |
| Dec 2019 | $42M | +25.6% | $3M | $3M | 7.5% |
| Dec 2018 | $33M | — | $-1M | $-1M | -4.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-7M | — | — | $-0.43 | — |
| Dec 2024 | $-12M | $1M | $-13M | $-0.40 | — |
| Dec 2023 | $3M | $1M | $2M | $-0.24 | — |
| Dec 2022 | $17M | $17M | $-0M | $0.15 | — |
| Dec 2021 | $33M | $58M | $-26M | $1.63 | — |
| Dec 2020 | $19M | $21M | $-2M | $0.80 | — |
| Dec 2019 | $2M | $1M | $2M | $0.07 | — |
| Dec 2018 | $-1M | $0M | $-2M | $-0.06 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $7M (-31.1% on a year earlier), net income $3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Sep 30, 20268-KCurrent reportOther events
- Aug 14, 20268-KCurrent reportOther events
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Jun 30, 20268-KCurrent reportOther events
- May 15, 20268-KCurrent reportOther events
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportShareholder vote
- Apr 10, 20268-KCurrent reportOther events
- Mar 27, 20268-KCurrent reportOther events
- Mar 27, 202610-KAnnual report · period to Dec 2025
- Mar 27, 2026DEF 14AProxy statement
- Dec 30, 20258-KCurrent reportOther events
Official filings of Retractable Technologies, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $38 M
- Operating income
- $-21 M
- Net income
- $-13 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $143 M
- Total liabilities
- $68 M
- Total equity
- $74 M
As of December-2025
Top 33 institutional investors in Retractable Technologies, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 581,736 | 0 (0.00%) | 1.94% | $0 M | Nov 13, 2026 |
| 2 | Eversept Partners, LP | 580,919 | 0 (0.00%) | 1.94% | $0 M | Nov 16, 2026 |
| 3 | Renaissance Technologies LLC | 407,389 | -34,018 (-7.71%) | 1.36% | $0 M | Nov 12, 2026 |
| 4 | BlackRock, Inc. | 241,121 | 0 (0.00%) | 0.81% | $0 M | Nov 13, 2026 |
| 5 | Geode Capital Management, LLC | 118,156 | -2,849 (-2.35%) | 0.39% | $0 M | Nov 6, 2026 |
| 6 | Bridgeway Capital Management, LLC | 87,444 | -1,099 (-1.24%) | 0.29% | $0 M | Nov 16, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 85,260 | 0 (0.00%) | 0.28% | $0 M | Nov 13, 2026 |
| 8 | Empowered Funds, LLC | 63,014 | New | 0.21% | $0 M | Nov 13, 2026 |
| 9 | State Street Corp | 59,796 | 0 (0.00%) | 0.20% | $0 M | Nov 12, 2026 |
| 10 | LPL Financial LLC | 46,116 | -1,450 (-3.05%) | 0.15% | $0 M | Nov 6, 2026 |
| 11 | Citadel Advisors LLC | 44,367 | -42,966 (-49.20%) | 0.15% | $0 M | Nov 16, 2026 |
| 12 | WealthTrust Axiom LLC | 42,333 | -9,000 (-17.53%) | 0.14% | $0 M | Nov 10, 2026 |
| 13 | Avidian Wealth Enterprises, LLC | 30,800 | 0 (0.00%) | 0.10% | $0 M | Oct 8, 2026 |
| 14 | Northern Trust Corp | 28,444 | 0 (0.00%) | 0.10% | $0 M | Nov 16, 2026 |
| 15 | Frisch Financial Group, Inc. | 19,000 | 0 (0.00%) | 0.06% | $0 M | Nov 10, 2026 |
| 16 | Susquehanna International Group, LLP | 12,318 | -66,539 (-84.38%) | 0.04% | $0 M | Nov 16, 2026 |
| 17 | Pasadena Private Wealth, LLC | 10,400 | 0 (0.00%) | 0.03% | $0 M | Nov 10, 2026 |
| 18 | CX Institutional | 7,000 | 0 (0.00%) | 0.02% | $0 M | Oct 2, 2026 |
| 19 | Jones Financial Companies Lllp | 6,400 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 20 | UBS Group AG | 5,987 | +1,648 (+37.98%) | 0.02% | $0 M | Nov 10, 2026 |
| 21 | Vanguard Global Advisers, LLC | 5,813 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 22 | Morgan Stanley | 3,430 | -100 (-2.83%) | 0.01% | $0 M | Nov 13, 2026 |
| 23 | Rockefeller Capital Management L.P. | 2,500 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 24 | Tower Research Capital LLC (TRC) | 2,193 | -445 (-16.87%) | 0.01% | $0 M | Nov 16, 2026 |
| 25 | Performa Ltd (US), LLC | 1,750 | 0 (0.00%) | 0.01% | $0 M | Nov 5, 2026 |
Show all 33: investors 26 to 33
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Royal Bank Of Canada | 1,099 | New | 0.00% | $0 M | Nov 16, 2026 |
| 27 | Citigroup Inc | 1,073 | New | 0.00% | $0 M | Nov 4, 2026 |
| 28 | Wells Fargo & Company/mn | 500 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 29 | IFP Advisors, Inc | 41 | New | 0.00% | $0 M | Oct 16, 2026 |
| 30 | Allworth Financial LP | 25 | New | 0.00% | $0 M | Nov 17, 2026 |
| 31 | Northwestern Mutual Wealth Management Co | 18 | New | 0.00% | $0 M | Nov 13, 2026 |
| 32 | SBI Securities Co., Ltd. | 8 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 33 | Barclays PLC | 6 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
Mutual funds holding Retractable Technologies, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 412,203 | $0 M | 1.4% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 169,533 | $0 M | 0.57% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 80,434 | $0 M | 0.27% | <0.01% | +35% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 64,113 | $0 M | 0.21% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 31,995 | $0 M | 0.11% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 15,739 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC | 9,430 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Retractable Technologies, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Thomas J. ShawPRESIDENT AND CEO, Director, 10% owner | Buy10b5-1 plan | +5,731 | $0.770 | $4 K | 15.83 M | Form 4 |
| filed | Thomas J. ShawPRESIDENT AND CEO, Director, 10% owner | Buy10b5-1 plan | +100 | $0.810 | $81 | 15.83 M | Form 4 |
| filed | Thomas J. ShawPRESIDENT AND CEO, Director, 10% owner | Buy10b5-1 plan | +7,500 | $0.830 | $6 K | 15.83 M | Form 4 |
| filed | Thomas J. ShawPRESIDENT AND CEO, Director, 10% owner | Buy10b5-1 plan | +15,000 | $0.860 | $13 K | 15.82 M | Form 4 |
| filed | Thomas J. ShawPRESIDENT AND CEO, Director, 10% owner | Buy10b5-1 plan | +35,000 | $0.920 | $32 K | 15.80 M | Form 4 |
| filed | Thomas J. ShawPRESIDENT AND CEO, Director, 10% owner | Buy10b5-1 plan | +34,506 | $0.940 | $32 K | 15.77 M | Form 4 |
| filed | Thomas J. ShawPRESIDENT AND CEO, Director, 10% owner | Buy10b5-1 plan | +356 | $0.950 | $338 | 15.73 M | Form 4 |
| filed | Thomas J. ShawPRESIDENT AND CEO, Director, 10% owner | Buy10b5-1 plan | +10,000 | $0.960 | $10 K | 15.73 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Retractable Technologies, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2022 | Q4 2022 | $4.8M |
| Q3 2022 | Q3 2022 | $0M |
| Q2 2022 | Q2 2022 | $0.3M |
| Q1 2022 | Q1 2022 | $2.5M |
| Q4 2021 | Q4 2021 | $2.4M |
| Q3 2021 | Q3 2021 | $2.7M |
| Q2 2021 | Q2 2021 | $0.2M |
| Q4 2013 | Q4 2013 | $0M |
| Q3 2013 | Q3 2013 | $0.5M |
| Q2 2013 | Q2 2013 | $0.3M |
| Q1 2013 | Q1 2013 | $0.1M |
| Q4 2012 | Q4 2012 | $0M |
Fails to deliver
- : 1,189 shares at $0.59
- : 149 shares at $0.73
- : 287 shares at $0.66
- : 1,444 shares at $0.70
- : 3,004 shares at $0.70
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Retractable Technologies, Inc. scorecard#
Passes 7 of the 22 checks that could be worked out: strongest in financial health (3 of 5), weakest in profitability (0 of 5). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.2×Price to book 0.2× against Medical Instruments's median of 3.9×.
- ✓Price to sales below its peers' median0.5×Price to sales 0.5× against Medical Instruments's median of 3.0×.
- ✗Free cash flow yield above 5%-73.6%Free cash flow is -73.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✓Revenue grew in the newest year15.8%Revenue up 15.8% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-26.1%-26.1% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-26.1%-26.1% a year against Medical Instruments's median of 5.0% (37 companies).
- ✗Earnings per share grew in the newest year-0.43 vs -0.40Diluted EPS -0.43 in fiscal 2025 against -0.40 the year before (report's currency).
- ✗Net income higher than five years earlier-$13 M-$13 M in fiscal 2025 against $24 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$13 MNet income -$13 M in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-55.3%-55.3% against Medical Instruments's median of 7.2% (46 companies).
- ✗Return on equity above 15%-15.6%-15.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-55.3%-55.3% in fiscal 2025 against -0.9% in 2022.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities6.6×Current ratio 6.57 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.01 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $2 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone0.52Z-score 0.52 (distress zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.0%Diluted shares down 0.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Retractable Technologies, Inc.'s statements, beside the median of Medical Instruments.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -55.3% | 7.2% | |
| Net margin | -32.9% | 3.8% | |
| Return on equity | -15.6% | 3.5% | |
| Revenue growth, 3 years a year | -26.1% | 5.0% | |
| Revenue growth | 15.8% | 8.9% | |
| Debt to equity | 0.01× | 0.46× |
4of 9on the Piotroski tests of financial strength
- Net loss of $13 million, the 3th loss-making year in a row.
- More cash than debt: net cash of $2 million.
Retractable Technologies, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 38+15.8%100% | 33−24.2%100% | 44−54.0%100% | 95−49.7%100% | 188+130%100% | 82+95.9%100% | 42+25.6%100% | 33−3.5%100% | 34+15.6%100% | 30—100% | |
| Cost of revenue | 38+12.2%99.9% | 34−1.2%103% | 34−48.2%79.1% | 67−28.4%70.2% | 93+107%49.4% | 45+62.2%54.8% | 28+20.0%66.2% | 23−6.0%69.3% | 25+25.9%71.1% | 19—65.3% | |
| Gross profit | 0.0—0.1% | −1.0−111%−3.1% | 9.1−67.8%20.9% | 28−70.4%29.8% | 95+158%50.6% | 37+162%45.2% | 14+38.3%33.8% | 10+2.5%30.7% | 10.0−3.6%28.9% | 10—34.7% | |
| Research and development | 0.7+0.2%1.8% | 0.7+16.0%2.0% | 0.6+10.5%1.3% | 0.5−41.7%0.6% | 0.9+56.9%0.5% | 0.6+11.3%0.7% | 0.5−16.9%1.2% | 0.6−16.1%1.9% | 0.7+29.5%2.1% | 0.6—1.9% | |
| Selling and marketing | 6.8+16.6%17.8% | 5.8+2.5%17.7% | 5.7+25.6%13.1% | 4.5+1.5%4.8% | 4.5+10.2%2.4% | 4.1−3.7%5.0% | 4.2−4.2%10.1% | 4.4−5.5%13.2% | 4.7+15.7%13.5% | 4.0—13.5% | |
| General and administrative | 13−5.8%33.4% | 14−5.3%41.0% | 14−40.5%32.8% | 24+38.3%25.3% | 17+109%9.2% | 8.3+29.1%10.1% | 6.4−5.2%15.4% | 6.8r6.8−18.7%20.4% | 8.4−5.1%24.2% | 8.8—29.5% | |
| Operating expenses | 21+5.7%55.5% | 20−2.5%60.7% | 21−29.2%47.2% | 29+27.9%30.7% | 23+75.9%12.1% | 13+15.9%15.8% | 11−5.5%26.7% | 12r12−14.1%35.5% | 14−0.7%39.9% | 14—46.4% | |
| Operating income | −21—−55.3% | −21—−63.9% | −11—−26.4% | −0.9−101%−0.9% | 73+202%38.5% | 24+710%29.4% | 3.0—7.1% | −1.3r−1.3—−4.0% | −3.8—−11.0% | −3.5—−11.8% | |
| Interest and finance income | — | — | — | — | — | 2.3+544%2.8% | 0.4+129%0.8% | 0.2r0.1+134%0.5% | 0.1+148%0.2% | 0.0—0.1% | |
| Interest expense and finance costs | 0.1−28.2%0.2% | 0.1−19.5%0.4% | 0.2−10.8%0.3% | 0.2−24.9%0.2% | 0.2−12.7%0.1% | 0.3+55.9%0.3% | 0.2−5.8%0.4% | 0.2−15.9%0.5% | 0.2−1.2%0.6% | 0.2—0.7% | |
| Income before tax | −12—−32.1% | −3.5—−10.7% | −8.9−273%−20.5% | 5.2−93.1%5.4% | 75+187%39.8% | 26+726%31.9% | 3.2—7.6% | −1.4—−4.1% | −3.9—−11.4% | −3.7—−12.4% | |
| Income tax | 0.3−96.5%0.8% | 8.4—25.3% | −1.9−2372%−4.4% | 0.1−99.6%0.1% | 19+921%10.0% | 1.9+23395%2.3% | 0.0—0.0% | −0.0—−0.0% | −0.2−16673%−0.5% | 0.0—0.0% | |
| Net income including minority interests | −13—−32.8% | −12—−36.0% | −7.0−238%−16.1% | 5.1−90.9%5.4% | 56+131%29.8% | 24+669%29.6% | 3.1—7.5% | −1.3—−4.0% | −3.7—−10.8% | −3.7—−12.4% | |
| Net income attributable to shareholders | −13—−32.8% | −12—−36.0% | −7.0−238%−16.1% | 5.1−90.9%5.4% | 56+131%29.8% | 24+669%29.6% | 3.1—7.5% | −1.3—−4.0% | −3.7—−10.8% | −3.7—−12.4% | |
| Earnings per share, basic | -0.43—— | -0.40—— | -0.24−260%— | 0.15−90.9%— | 1.65+106%— | 0.80+1043%— | 0.07—— | -0.06—— | -0.14—— | -0.15—— | |
| Earnings per share, diluted | -0.43—— | -0.40—— | -0.24−260%— | 0.15−90.8%— | 1.63+104%— | 0.80+1043%— | 0.07—— | -0.06—— | -0.14—— | -0.15—— | |
| Shares, weighted average (basic) | 300.0%— | 300.0%— | 30−9.0%— | 33−2.9%— | 34+2.1%— | 33+1.5%— | 33+0.0%— | 33+2.2%— | 32+8.9%— | 29—— | |
| Shares, weighted average (diluted) | 300.0%— | 300.0%— | 30−9.2%— | 33−3.7%— | 34+2.8%— | 33+1.9%— | 33+0.0%— | 33+2.2%— | 32+8.9%— | 29—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 2.6−38.9%1.8% | 4.2−66.6%2.6% | 13−35.8%7.1% | 20−32.4%10.1% | 29+66.0%14.1% | 18+196%16.7% | 5.9−38.5%15.1% | 9.6−35.2%26.1% | 15−8.2%39.0% | 16—41.8% | |
| Receivables | 7.9+1.5%5.5% | 7.8−27.0%4.8% | 11+121%5.9% | 4.8−86.1%2.5% | 35+65.0%16.9% | 21r33+222%20.1% | 6.6+33.6%16.8% | 4.9−3.8%13.3% | 5.1+56.2%13.4% | 3.3—8.4% | |
| Inventory | 17−10.4%12.1% | 19+9.1%11.9% | 18−15.0%9.8% | 21+0.5%10.6% | 21+101%10.0% | 10+37.4%9.8% | 7.5−1.3%19.0% | 7.5+21.6%20.4% | 6.2−11.6%16.3% | 7.0—18.1% | |
| Other current assets | 0.7−5.5%0.5% | 0.8−21.0%0.5% | 1.0−24.8%0.5% | 1.3r1.3+80.4%0.6% | 0.7+2.6%0.3% | 0.7+7.7%0.7% | 0.6−1.5%1.6% | 0.6+54.2%1.7% | 0.4+117%1.1% | 0.2—0.5% | |
| Current assets | 63−13.9%44.2% | 73−5.6%45.6% | 78−12.6%43.2% | 89−15.0%45.4% | 105+50.4%50.7% | 69+145%66.2% | 28+9.9%72.5% | 26r24−2.9%69.9% | 27−0.3%69.7% | 27—68.8% | |
| Property, plant and equipment | 79−9.4%55.5% | 87−6.6%54.3% | 93−6.7%52.0% | 100+13.9%51.2% | 88+185%42.6% | 31+190%29.4% | 11−2.0%27.1% | 11−4.4%29.4% | 11−6.1%29.8% | 12—31.2% | |
| Right-of-use (leased) assets | — | — | — | — | — | 0.0−52.8%0.0% | 0.1−49.5%0.2% | 0.2—0.4% | — | — | |
| Total assets | 143−11.3%100% | 161−10.5%100% | 180−8.2%100% | 196−5.2%100% | 206+96.5%100% | 105+168%100% | 39+6.0%100% | 37r37−3.1%100% | 38−1.6%100% | 39—100% | |
| Accounts payable | 5.3+24.5%3.7% | 4.3−10.2%2.7% | 4.8−25.4%2.7% | 6.4−68.6%3.3% | 20+25.5%9.9% | 16+225%15.5% | 5.0−6.7%12.8% | 5.4+8.3%14.5% | 5.0+10.9%13.0% | 4.5—11.5% | |
| Debt due within a year | — | 0.3+9.4%0.2% | 0.3+6.3%0.2% | 0.3−1.1%0.1% | 0.3−72.0%0.1% | 1.0+295%1.0% | 0.3−35.8%0.7% | 0.4−1.1%1.1% | 0.4−4.5%1.1% | 0.4—1.1% | |
| Current liabilities | 9.6+9.3%6.7% | 8.8−6.4%5.5% | 9.4−22.7%5.2% | 12−65.6%6.2% | 35+26.6%17.1% | 28+238%26.6% | 8.3−4.2%21.1% | 8.6r8.5+9.1%23.3% | 7.9+10.1%20.7% | 7.2—18.5% | |
| Long-term debt | — | 0.9−27.0%0.6% | 1.2−19.6%0.7% | 1.5−15.5%0.8% | 1.8−33.1%0.9% | 2.7+14.0%2.6% | 2.4−9.9%6.1% | 2.6−14.3%7.1% | 3.1−11.9%8.1% | 3.5—9.0% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | 0.1—0.2% | — | — | |
| Total liabilities | 68−7.2%47.9% | 74−8.5%45.8% | 80−9.8%44.7% | 89−16.8%45.6% | 107+94.5%51.9% | 55+418%52.5% | 11−6.2%27.1% | 11r11+3.3%30.7% | 11+2.9%28.8% | 11—27.5% | |
| Retained earnings | 14−48.0%9.7% | 27−31.2%16.6% | 39−15.7%21.6% | 46+11.8%23.5% | 41—20.0% | −9.7—−9.2% | −34—−86.5% | −37—−100% | −36—−93.6% | −32—−82.4% | |
| Shareholders' equity | 74−14.7%52.1% | 87−12.2%54.2% | 99−6.8%55.3% | 107+7.4%54.4% | 99+98.8%48.1% | 50+74.8%47.5% | 29+11.4%72.9% | 26−5.7%69.3% | 27−3.3%71.2% | 28—72.5% | |
| Total liabilities and equity | 143−11.3%100% | 161−10.5%100% | 180−8.2%100% | 196−5.2%100% | 206+96.5%100% | 105+168%100% | 39+6.0%100% | 37r37−3.1%100% | 38−1.6%100% | 39—100% | |
| Shares outstanding | 300.0%— | 300.0%— | 300.0%— | 30−10.6%— | 33−1.4%— | 34+3.9%— | 33+0.0%— | 330.0%— | 33+10.1%— | 30—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 7.8+2.6%20.3% | 7.6+0.6%22.9% | 7.5+63.5%17.3% | 4.6+266%4.9% | 1.3+51.1%0.7% | 0.8−2.3%1.0% | 0.9−3.9%2.0% | 0.9+6.2%2.7% | 0.8−4.3%2.4% | 0.9—2.9% | |
| Share-based compensation | — | 0—0.0% | 0−100%0.0% | 10r10+177%10.7% | 3.7—1.9% | 0—0.0% | 0—0.0% | 0−100%0.0% | 0.7+73.4%1.9% | 0.4—1.3% | |
| Cash from operating activities | −7.1—−18.5% | −12−518%−35.0% | 2.8−83.5%6.3% | 17−48.9%17.7% | 33+72.6%17.4% | 19+766%23.2% | 2.2—5.3% | −1.2—−3.6% | −2.9—−8.5% | −0.8—−2.7% | |
| Capital expenditure | — | −1.4—−4.4% | −0.9—−2.0% | −17—−17.7% | −58—−31.0% | −21—−25.7% | −0.6—−1.5% | −0.4—−1.1% | −0.1—−0.3% | −1.9—−6.5% | |
| Cash from investing activities | 6.0+63.5%15.6% | 3.7—11.1% | −11—−24.7% | −31—−32.9% | −63—−33.5% | −19—−23.6% | −5.3—−12.6% | −3.4—−10.1% | −0.1—−0.3% | −1.9—−6.5% | |
| Debt issued | — | — | — | — | — | 1.4—1.7% | — | — | — | 0.5—1.8% | |
| Debt repaid | −0.3—−0.9% | −0.3—−0.9% | −0.3—−0.6% | −0.3—−0.3% | −0.3—−0.1% | −0.3—−0.3% | −0.4—−1.0% | −0.4—−1.3% | −0.4—−1.3% | −0.3—−0.9% | |
| Shares issued | — | — | — | — | 5.3—2.8% | — | — | — | 2.4—6.8% | — | |
| Shares bought back | — | — | — | −7.6—−8.0% | −5.3—−2.8% | — | — | — | — | — | |
| Cash from financing activities | −0.6—−1.5% | −0.5−157%−1.6% | 0.9−81.1%2.2% | 5.0−88.1%5.3% | 42+250%22.2% | 12—14.6% | −0.6—−1.5% | −0.7−139%−2.0% | 1.7+89.0%4.9% | 0.9—3.0% | |
| Change in cash | −1.6—−4.3% | −8.4—−25.5% | −7.1—−16.2% | −9.4−181%−10.0% | 12−0.3%6.2% | 12—14.2% | −3.7—−8.9% | −5.2—−15.7% | −1.3—−3.8% | −1.8—−6.2% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 34−11.2%100% | 7.2−31.1%100% | 7.2−13.5%100% | 9.4*+4.0%100% | 10−2.5%100% | 10+73.2%100% | 8.3+9.2%100% | 9.1*−36.5%100% | 10+0.1%100% | 6.0—100% | 7.6—100% | 14*—100% | 10—100% | |
| Cost of revenue | 34−15.7%101% | 7.0−33.6%97.3% | 8.0−3.4%112% | 11*−5.2%116% | 8.4−18.9%83.3% | 11+63.6%101% | 8.3+45.6%100% | 12*−9.3%127% | 10+72.3%100% | 6.4—107% | 5.7—75.0% | 13*—89.2% | 6.0—58.2% | |
| Gross profit | −0.5—−1.4% | 0.2—2.7% | −0.8—−11.7% | −1.5*—−16.2% | 1.7—16.7% | −0.1—−1.0% | −0.0−100%−0.0% | −2.5*−262%−27.5% | −0.0−100%−0.1% | −0.4—−7.0% | 1.9—25.0% | 1.5*—10.8% | 4.3—41.8% | |
| Research and development | 0.7−0.3%2.0% | 0.2+17.0%2.6% | 0.2−10.9%2.4% | 0.1*−20.9%1.3% | 0.2+14.2%2.0% | 0.2−19.6%1.5% | 0.2+34.4%2.3% | 0.2*−2.4%1.7% | 0.2+15.7%1.7% | 0.2—3.3% | 0.1—1.9% | 0.2*—1.1% | 0.2—1.5% | |
| Selling and marketing | 6.8+10.0%20.1% | 1.5−7.6%21.3% | 1.7+8.3%24.2% | 2.0*+65.8%20.9% | 1.6−9.5%15.7% | 1.7+12.7%15.9% | 1.6+11.6%19.3% | 1.2*−17.5%13.1% | 1.7+27.8%16.9% | 1.5—24.5% | 1.4—18.9% | 1.4*—10.1% | 1.4—13.2% | |
| General and administrative | 14+8.4%40.5% | 3.6+12.9%50.2% | 3.4+18.8%47.7% | 3.1*−7.3%33.2% | 3.6+11.2%35.3% | 3.2−12.7%30.7% | 2.9−12.9%34.7% | 3.4*+24.4%37.2% | 3.2−14.5%30.9% | 3.7—60.9% | 3.3—43.6% | 2.7*—19.0% | 3.7—36.2% | |
| Operating expenses | 22+13.5%65.5% | 5.3+6.2%74.1% | 5.3+14.0%74.3% | 6.2*+30.8%65.5% | 5.3+4.3%52.9% | 5.0−6.0%48.1% | 4.7−4.3%56.4% | 4.7*+9.4%52.1% | 5.1−2.6%49.5% | 5.3—88.6% | 4.9—64.3% | 4.3*—30.2% | 5.3—50.9% | |
| Operating income | −23—−66.9% | −5.1—−71.5% | −6.2—−85.9% | −7.7*—−81.7% | −3.7—−36.2% | −5.1—−49.1% | −4.7—−56.4% | −7.2*—−79.6% | −5.1—−49.6% | −5.8—−95.6% | −3.0—−39.3% | −2.8*—−19.4% | −0.9—−9.1% | |
| Interest expense and finance costs | 0.1−21.0%0.2% | 0.0−16.0%0.3% | 0.0−12.9%0.3% | 0.0*−19.1%0.2% | 0.0−32.5%0.2% | 0.0−30.0%0.2% | 0.0−29.9%0.3% | 0.0*−23.8%0.3% | 0.0−15.5%0.3% | 0.0—0.5% | 0.0—0.4% | 0.0*—0.2% | 0.0—0.3% | |
| Income before tax | −3.4—−9.9% | 2.8—39.3% | −4.2—−58.8% | −2.3*−162%−24.9% | 0.4—3.7% | −0.1—−0.8% | −10−2084%−123% | 3.8*—41.6% | −2.0—−18.9% | −5.9—−97.1% | 0.5—6.8% | −0.0*—−0.3% | −5.3—−51.2% | |
| Income tax | 0.0−97.1%0.0% | 0.0+1.3%0.0% | 0.0−99.4%0.0% | 0.0*+1.7%0.0% | 0.0—0.0% | 0.0−100.0%0.0% | 0.3+234%3.4% | 0.0*−93.2%0.0% | −0.0—−0.3% | 8.3—138% | 0.1—1.1% | 0.0*—0.2% | −1.2—−11.9% | |
| Net income including minority interests | −3.4—−9.9% | 2.8*—39.3% | −4.2—−58.9% | −2.3*−162%−24.9% | 0.4*—3.7% | −0.1*—−0.8% | −11−2546%−127% | 3.8*—41.6% | −1.9*—−18.6% | −14*—−235% | 0.4—5.7% | −0.1*—−0.5% | −4.1*—−39.3% | |
| Net income attributable to shareholders | −3.4—−9.9% | 2.8—39.3% | −4.2—−58.9% | −2.3*−162%−24.9% | 0.4—3.7% | −0.1—−0.8% | −11−2546%−127% | 3.8*—41.6% | −1.9—−18.6% | −14—−235% | 0.4—5.7% | −0.1*—−0.5% | −4.1—−39.3% | |
| Earnings per share, basic | — | 0.09—— | -0.14—— | — | 0.01—— | 0.00—— | -0.35−3600%— | — | -0.07—— | -0.48—— | 0.01—— | — | -0.14—— | |
| Earnings per share, diluted | — | 0.09—— | -0.14—— | — | 0.01—— | 0.00—— | -0.35−3600%— | — | -0.07—— | -0.48—— | 0.01—— | — | -0.14—— | |
| Shares, weighted average (basic) | 300.0%— | 300.0%— | 300.0%— | — | 300.0%— | 300.0%— | 300.0%— | — | 300.0%— | 30—— | 30—— | — | 30—— | |
| Shares, weighted average (diluted) | 300.0%— | 300.0%— | 300.0%— | — | 300.0%— | 300.0%— | 30−0.0%— | — | 300.0%— | 30—— | 30—— | — | 30—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2.6—1.9% | 2.6−13.3%1.9% | 2.8−18.2%2.0% | 2.6−38.9%1.8% | 3.4−12.1%2.4% | 3.0−55.6%2.1% | 3.4−66.2%2.3% | 4.2−66.6%2.6% | 3.9−65.2%2.5% | 6.9—4.3% | 10—5.7% | 13—7.1% | 11—6.2% | |
| Receivables | 9.0—6.4% | 9.0+11.7%6.4% | 7.0+30.2%5.1% | 7.9+1.5%5.5% | 8.4−2.7%5.8% | 8.1+72.4%5.5% | 5.4−27.8%3.6% | 7.8−27.0%4.8% | 8.7+6.0%5.5% | 4.7—2.9% | 7.4—4.2% | 11—5.9% | 8.2—4.5% | |
| Inventory | 16—11.2% | 16−22.1%11.2% | 16−22.4%11.9% | 17−10.4%12.1% | 20−4.3%13.9% | 20−7.1%13.9% | 21+8.7%14.2% | 19+9.1%11.9% | 21−5.2%13.5% | 22—13.7% | 19—11.1% | 18—9.8% | 22—12.4% | |
| Other current assets | 0.8—0.6% | 0.8+5.1%0.6% | 0.6−13.5%0.5% | 0.7−5.5%0.5% | 0.7−28.6%0.5% | 0.7−15.2%0.5% | 0.7−28.3%0.5% | 0.8−21.0%0.5% | 1.0−11.5%0.6% | 0.9—0.5% | 1.0—0.6% | 1.0—0.5% | 1.1—0.6% | |
| Current assets | 66—46.5% | 66+4.6%46.5% | 60−5.8%43.6% | 63−13.9%44.2% | 64−6.7%43.8% | 63−10.7%42.8% | 64−15.9%42.6% | 73−5.6%45.6% | 69−11.6%43.6% | 71—43.9% | 76—43.0% | 78—43.2% | 78—42.9% | |
| Property, plant and equipment | 75—53.3% | 75−10.2%53.3% | 77−9.6%56.2% | 79−9.4%55.5% | 82−7.5%56.2% | 84−6.7%57.1% | 86−6.8%57.3% | 87−6.6%54.3% | 89−6.4%56.4% | 90—56.0% | 92—52.2% | 93—52.0% | 95—52.4% | |
| Total assets | 142—100% | 142−3.7%100% | 138−7.8%100% | 143−11.3%100% | 146−7.2%100% | 147−8.5%100% | 149−15.2%100% | 161−10.5%100% | 158−13.1%100% | 161—100% | 176—100% | 180—100% | 182—100% | |
| Accounts payable | 6.7—4.7% | 6.7+65.0%4.7% | 5.4+14.0%3.9% | 5.3+24.5%3.7% | 4.6+40.7%3.1% | 4.1+30.4%2.8% | 4.7+82.1%3.2% | 4.3−10.2%2.7% | 3.3−4.2%2.1% | 3.1—1.9% | 2.6—1.5% | 4.8—2.7% | 3.4—1.9% | |
| Debt due within a year | — | — | — | — | 0.4+10.4%0.2% | 0.3+10.1%0.2% | 0.3+10.3%0.2% | 0.3+9.4%0.2% | 0.3+9.4%0.2% | 0.3—0.2% | 0.3—0.2% | 0.3—0.2% | 0.3—0.2% | |
| Current liabilities | 13—9.4% | 13+48.7%9.4% | 10+10.0%7.6% | 9.6+9.3%6.7% | 9.6+20.1%6.6% | 9.0+21.1%6.1% | 9.5+38.2%6.4% | 8.8−6.4%5.5% | 8.0−13.4%5.1% | 7.4—4.6% | 6.9—3.9% | 9.4—5.2% | 9.3—5.1% | |
| Long-term debt | — | — | — | — | 0.6−36.8%0.4% | 0.7−33.0%0.5% | 0.8−30.0%0.5% | 0.9−27.0%0.6% | 1.0−24.8%0.6% | 1.1—0.7% | 1.2—0.7% | 1.2—0.7% | 1.3—0.7% | |
| Total liabilities | 69—48.6% | 69−2.5%48.6% | 68−7.1%49.1% | 68−7.2%47.9% | 70−6.3%47.6% | 71−6.2%48.0% | 73−4.7%48.7% | 74−8.5%45.8% | 74−9.4%47.1% | 75—46.8% | 76—43.4% | 80—44.7% | 82—45.2% | |
| Retained earnings | 12—8.7% | 12−22.6%8.7% | 9.6−40.5%7.0% | 14−48.0%9.7% | 16−29.1%11.1% | 16−36.0%10.9% | 16−58.9%10.8% | 27−31.2%16.6% | 23−41.0%14.5% | 25—15.5% | 39—22.3% | 39—21.6% | 39—21.4% | |
| Shareholders' equity | 73—51.4% | 73−4.7%51.4% | 70−8.5%50.9% | 74−14.7%52.1% | 77−8.0%52.4% | 76−10.5%52.0% | 77−23.1%51.3% | 87−12.2%54.2% | 83−16.1%52.9% | 85—53.2% | 100—56.6% | 99—55.3% | 99—54.8% | |
| Total liabilities and equity | 142—100% | 142−3.7%100% | 138−7.8%100% | 143−11.3%100% | 146−7.2%100% | 147−8.5%100% | 149−15.2%100% | 161−10.5%100% | 158−13.1%100% | 161—100% | 176—100% | 180—100% | 182—100% | |
| Shares outstanding | 30—— | 300.0%— | 300.0%— | 300.0%— | 300.0%— | 300.0%— | 300.0%— | 300.0%— | 300.0%— | 30—— | 30—— | 30—— | 30—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 7.8+3.5%23.0% | 1.9*+1.3%26.3% | 1.9+1.2%26.5% | 2.1*+13.7%22.7% | 1.9*−2.1%18.5% | 1.9*−0.8%17.9% | 1.9−0.3%22.7% | 1.9*+10.9%20.8% | 1.9*−1.8%18.4% | 1.9*—31.3% | 1.9—24.9% | 1.7*—11.9% | 1.9*—18.8% | |
| Cash from operating activities | −5.0—−14.6% | −1.7*—−24.1% | −1.4—−19.1% | −0.6*—−6.3% | −1.3*—−12.5% | −3.7*—−35.8% | −1.5—−17.8% | −1.1*−158%−12.2% | −5.7*−173%−55.4% | −2.7*—−44.8% | −2.0—−26.6% | 1.9*—13.3% | 7.8*—75.5% | |
| Capital expenditure | — | −0.0*—−0.4% | −0.0—−0.1% | — | −0.1*—−0.9% | −0.3*—−3.2% | −0.1—−1.0% | −0.3*—−3.3% | −0.8*—−7.7% | −0.1*—−2.0% | −0.2—−3.0% | −0.2*—−1.1% | −0.1*—−1.4% | |
| Cash from investing activities | 5.2−41.0%15.3% | 1.8*−49.0%25.1% | 1.7+122%23.6% | −0.1*−107%−1.2% | 1.8*−38.5%17.8% | 3.5*—33.9% | 0.8—9.2% | 1.6*—17.2% | 2.9*—28.3% | −0.3*—−5.3% | −0.5—−6.6% | −0.3*—−2.4% | −0.6*—−5.4% | |
| Debt repaid | −0.4—−1.0% | −0.1*—−1.3% | −0.1—−1.2% | −0.1*—−0.9% | −0.1*—−0.8% | −0.1*—−0.8% | −0.1—−1.0% | −0.1*—−0.9% | −0.1*—−0.7% | −0.1*—−1.2% | −0.1—−1.0% | −0.1*—−0.5% | −0.1*—−0.7% | |
| Cash from financing activities | −0.6—−1.9% | −0.2*—−2.8% | −0.1—−2.0% | −0.1*—−1.5% | −0.1*—−1.4% | −0.1*—−1.3% | −0.1—−1.7% | −0.1*—−1.5% | −0.1*—−1.3% | −0.1*—−2.2% | −0.1—−1.7% | −0.1*—−1.0% | −0.1*—−1.2% | |
| Change in cash | −0.4—−1.2% | −0.1*—−1.7% | 0.2—2.5% | −0.9*−369%−9.1% | 0.4*—4.0% | −0.3*—−3.2% | −0.9—−10.3% | 0.3*−77.4%3.5% | −2.9*−141%−28.4% | −3.2*—−52.4% | −2.7—−35.0% | 1.4*—9.9% | 7.1*—68.8% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Retractable Technologies, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Syringes$25 M65%+10%
- EasyPoint Needles$12 M31%+33%
- Blood Collection Products$1 M3.6%-4.2%
- Other Products$0 M0.1%-20%
Business segments
- Single reportable segment$38 M100%+16%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Retractable Technologies, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Thomas J. Shaw | $1.2 M | $1.2 M | $304 K | $7 (peers $115) |
| 2024Thomas J. Shaw | $1.2 M | $1.2 M | $279 K | $7 (peers $107) |
| 2023Thomas J. Shaw | $1.1 M | $1.1 M | $280 K | $10 (peers $99) |
| 2022Thomas J. Shaw | $1.1 M | $8.6 M | $276 K | $15 (peers $97) |
| 2021Thomas J. Shaw | $11.5 M | $4.0 M | $1.3 M | $65 (peers $121) |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Retractable Technologies, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Shareholder vote 3
Source: SEC EDGAR, Form 8-K item numbers · as of May 13, 2026
Lobbying by Retractable Technologies, Inc.#
$120 K spent on lobbying the US Congress and federal agencies in 2022, most often on health issues and manufacturing.
- Health Issues3 reports
- Manufacturing3 reports
Lobbying firms hired in 2022
Tiber Creek Group $120 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $120 K | — | 4 |
| 2021 | $180 K | — | 4 |
| 2020 | $110 K | — | 5 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Retractable Technologies, Inc.”, “Retractable Technologies, Inc. (RTI)” and “Retractable Technologies, Inc. (RT)”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Retractable Technologies, Inc.#
1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $73 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Biomedical Device Compliance and Regulatory AffairBioengineers and Biomedical Engineers | 1 | $73 K |
Where: Little Elm, TX 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Retractable Technologies Inc and Retractable Technologies Inc
Product recalls by Retractable Technologies, Inc.#
1 recalls since 2015, 477,600 units in the notices that give a number. Medical devices (FDA): 1.
| Date | What and why | Units | Notice |
|---|---|---|---|
| EasyPoint Needle, 25G x 5/8", REF: 82091The needle cannula of a retractable needle may detach from the needle holder in the patient.Medical devicesClass II | 477,600 | Z-1293-2024 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
How Retractable Technologies, Inc. compares in Medical Instruments
- Market cap$18 M · higher than 3% of 116
- Revenue$38 M · higher than 13% of 120
- Net margin-10.0% · higher than 14% of 114
- Revenue growth15.8% · higher than 73% of 49
- Price / sales0.5× · lower than 95% of 85
- Price / book0.2× · lowest of 84
- FCF yield-73.6% · higher than 5% of 39
Peer comparison · Medical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Retractable Technologies, Inc.🇺🇸 | $18 M | — | -10.0% | +15.8% |
| Intuitive Surgical, Inc.🇺🇸 | $155.6 B | 52.6× | 25.5% | +20.5% |
| EssilorLuxottica S.A.🇫🇷 | $88.0 B | 32.1× | 8.1% | +4.5% |
| HOYA Corporation🇯🇵 | $56.2 B | 32.8× | 25.4% | — |
| Becton, Dickinson and Company🇺🇸 | $54.0 B | 57.4× | 4.2% | +8.2% |
| Alcon Inc.🇨🇭 | $37.1 B | 37.9× | 9.4% | +4.9% |
| ResMed Inc.🇺🇸 | $35.3 B | 22.1× | 27.8% | +9.8% |
| West Pharmaceutical Services, Inc.🇺🇸 | $27.1 B | 42.4× | 18.8% | +6.3% |
| Terumo Corporation🇯🇵 | $24.9 B | 27.0× | 12.0% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 9, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Retractable Technologies, Inc.? Verify and update this profile — free
Show Retractable Technologies, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.